Galsulfase (Naglazyme) [Internet], PMID: 28121110
Lysosomal storage diseases, PMID: 29152458
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI, PMID: 24108527
Galsulfase, PMID: 16521329
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations, PMID: 32340185
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI, PMID: 26943923
Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB, PMID: 16128602
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy, PMID: 22669363
Mucopolysaccharidosis VI, PMID: 20385007
Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase), PMID: 18709516
Rapid Desensitization for Immediate Hypersensitivity to Galsulfase Therapy in Patients with MPS VI, PMID: 26951141
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase), PMID: 18607760
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance, PMID: 31142378
Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series, PMID: 27134829
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase, PMID: 23557332
Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy, PMID: 18418554
Is premedication a necessity before galsulfase replacement therapy?, PMID: 27346567
Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme], PMID: 23244660
Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review, PMID: 30740728
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI, PMID: 23535281
Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]), PMID: 18250117
Enzyme Replacement Therapy may Affect Blood Immunosuppressant Monitoring, PMID: 32379593
Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program, PMID: 31324526
The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), PMID: 28457718
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures, PMID: 21434527
Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program, PMID: 30834539
Therapy for the mucopolysaccharidoses, PMID: 22210671
Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively, PMID: 18923918
Lysosomal storage diseases, PMID: 18720909
Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI, PMID: 21506914
Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome), PMID: 25518809
A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase, PMID: 19851471
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study, PMID: 24764221
Enzymes approved for human therapy: indications, mechanisms and adverse effects, PMID: 25648140
Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation, PMID: 20800524
Enzyme replacement therapy for the management of the mucopolysaccharidoses, PMID: 20040314
Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy, PMID: 33775523
[Enzyme replacement therapy of lysosomal storage diseases], PMID: 21211680
Early initiation of enzyme replacement therapy for the mucopolysaccharidoses, PMID: 24388732
Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations, PMID: 26776148
Thrombocytopenia associated with galsulfase treatment, PMID: 20670992
Current enzyme replacement therapy for the treatment of lysosomal storage diseases, PMID: 19725195
Home treatment of type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome) an alternative at this time of COVID-19 pandemic: A case in Peru, PMID: 33363956
[Management of mucopolysaccharidosis type VI in adults], PMID: 26502669
[Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy], PMID: 24862809
[Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI], PMID: 31582674
Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study, PMID: 33678523
Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype, PMID: 21917494
Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis, PMID: 19852785
[Overview of enzyme replacement therapy in mucopolysaccharidosis], PMID: 17546776
Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study., PMID:40510111
Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15 years follow-up., PMID:40381595
Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials., PMID:40317013
Histopathological and Clinical-Genetic Analysis of Corneal Specimens in Maroteaux-Lamy Syndrome., PMID:40079783
Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database., PMID:39161895
Novel chorioretinal findings in two siblings with mucopolysaccharidosis type VI., PMID:35658818
Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report., PMID:35078524
Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan., PMID:34987750
Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series., PMID:34666789
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI., PMID:34533215
Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy., PMID:33775523
Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study., PMID:33678523
Home treatment of type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome) an alternative at this time of COVID-19 pandemic: A case in Peru., PMID:33363956
Enzyme Replacement Therapy may Affect Blood Immunosuppressant Monitoring., PMID:32379593
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations., PMID:32340185
[Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI]., PMID:31582674
Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program., PMID:31324526
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance., PMID:31142378
Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program., PMID:30834539
Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review., PMID:30740728
Family study of a novel mutation of mucopolysaccharidosis type VI with a severe phenotype and good response to enzymatic replacement therapy: Case report., PMID:30335002
Lysosomal storage diseases., PMID:29152458
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up., PMID:28983456
The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)., PMID:28457718
Is premedication a necessity before galsulfase replacement therapy?, PMID:27346567
A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI., PMID:27164636
Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series., PMID:27134829
Rapid Desensitization for Immediate Hypersensitivity to Galsulfase Therapy in Patients with MPS VI., PMID:26951141
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI., PMID:26943923
Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome., PMID:26920906
Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations., PMID:26776148
[Management of mucopolysaccharidosis type VI in adults]., PMID:26502669
Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children., PMID:28649537
Enzymes approved for human therapy: indications, mechanisms and adverse effects., PMID:25648140
Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome)., PMID:25518809
[Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy]., PMID:24862809
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study., PMID:24764221
Early initiation of enzyme replacement therapy for the mucopolysaccharidoses., PMID:24388732
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI., PMID:24108527
Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases., PMID:24060239
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase., PMID:23557332
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI., PMID:23535281
Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme]., PMID:23244660
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy., PMID:22669363
Therapy for the mucopolysaccharidoses., PMID:22210671
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)., PMID:22127392
Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report., PMID:22056033
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI., PMID:21930407
For research use only. Not for human or drug use.
